Universität zu Köln

Wick, Wolfgang ORCID: 0000-0002-6171-634X, Roth, Patrick, Hartmann, Christian, Hau, Peter ORCID: 0000-0003-3894-5053, Nakamura, Makoto, Stockhammer, Florian ORCID: 0000-0002-0525-5956, Sabel, Michael C., Wick, Antje, Koeppen, Susanne, Ketter, Ralf, Vajkoczy, Peter, Eyupoglu, Ilker, Kalff, Rolf, Pietsch, Torsten, Happold, Caroline, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Schmidt-Graf, Friederike, Bamberg, Michael, Reifenberger, Guido, Platten, Michael ORCID: 0000-0002-4746-887X, von Deimling, Andreas ORCID: 0000-0002-5863-540X, Meisner, Christoph, Wiestler, Benedikt and Weller, Michael ORCID: 0000-0002-1748-174X (2016). Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 18 (11). S. 1529 - 1538. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866

Full text not available from this repository.

Abstract

Background. Optimal treatment and precise classification for anaplastic glioma are needed. Methods. The objective for long-term follow-up of NOA-04 is to optimize the treatment sequence for patients with anaplastic gliomas. Patients were randomized 2: 1: 1 to receive the standard radiotherapy (RT) (arm A), procarbazine, lomustine and vincristine (PCV) (arm B1), or temozolomide (TMZ) (arm B2). Results. Primary endpoint was time-to-treatment-failure (TTF), defined as progression after 2 lines of therapy or any time before if no further therapy was administered. Exploratory analyses examined associations of molecular marker status with TTF, progression-free survival (PFS), and overall survival (OS). At 9.5 (95% CI: 8.6-10.2) years, no difference between arms (A vs B1/B2) was observed: median TTF (4.6 [3.4-5.1] y vs 4.4 [3.3-5.3) y), PFS (2.5 [1.3-3.5] y vs 2.7 [1.9-3.2] y), and OS (8 [5.5-10.3] y vs 6.5 [5.4-8.3] y). Oligodendroglial versus astrocytic histology-but more so the subgroups according to CpG island methylator phenotype (CIMP) and 1p/19q co-deletion status-revealed a strong prognostic value of CIMPpos with (CIMPcodel) versus without 1p/19 co-deletion (CIMPnon-codel) versus CIMPneg. but no differential efficacy of RT versus chemotherapy for any of the endpoints. PFS was better for PCV-than for TMZ-treated patients with CIMPcodel tumors (HR B1 vs B2 0.39 [0.17-0.92], P = .31). In CIMPneg. tumors, hypermethylation of the O6-methyl-guanyl-DNA methyltransferase promoter (MGMT) provided a risk reduction for PFS with chemotherapy. Conclusions. There is no differential activity of primary chemotherapy versus RT in any subgroup of anaplastic glioma. Molecular diagnosis is superior to histology. Trial Registration: clinicaltrials.gov Identifier: NCT00717210.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Wick, Wolfgang UNSPECIFIED orcid.org/0000-0002-6171-634X UNSPECIFIED Roth, Patrick UNSPECIFIED UNSPECIFIED UNSPECIFIED Hartmann, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Hau, Peter UNSPECIFIED orcid.org/0000-0003-3894-5053 UNSPECIFIED Nakamura, Makoto UNSPECIFIED UNSPECIFIED UNSPECIFIED Stockhammer, Florian UNSPECIFIED orcid.org/0000-0002-0525-5956 UNSPECIFIED Sabel, Michael C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wick, Antje UNSPECIFIED UNSPECIFIED UNSPECIFIED Koeppen, Susanne UNSPECIFIED UNSPECIFIED UNSPECIFIED Ketter, Ralf UNSPECIFIED UNSPECIFIED UNSPECIFIED Vajkoczy, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Eyupoglu, Ilker UNSPECIFIED UNSPECIFIED UNSPECIFIED Kalff, Rolf UNSPECIFIED UNSPECIFIED UNSPECIFIED Pietsch, Torsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Happold, Caroline UNSPECIFIED UNSPECIFIED UNSPECIFIED Galldiks, Norbert UNSPECIFIED orcid.org/0000-0002-2485-1796 UNSPECIFIED Schmidt-Graf, Friederike UNSPECIFIED UNSPECIFIED UNSPECIFIED Bamberg, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Reifenberger, Guido UNSPECIFIED UNSPECIFIED UNSPECIFIED Platten, Michael UNSPECIFIED orcid.org/0000-0002-4746-887X UNSPECIFIED von Deimling, Andreas UNSPECIFIED orcid.org/0000-0002-5863-540X UNSPECIFIED Meisner, Christoph UNSPECIFIED UNSPECIFIED UNSPECIFIED Wiestler, Benedikt UNSPECIFIED UNSPECIFIED UNSPECIFIED Weller, Michael UNSPECIFIED orcid.org/0000-0002-1748-174X UNSPECIFIED
URN:	urn:nbn:de:hbz:38-257943
DOI:	10.1093/neuonc/now133
Journal or Publication Title:	Neuro-Oncology
Volume:	18
Number:	11
Page Range:	S. 1529 - 1538
Date:	2016
Publisher:	OXFORD UNIV PRESS INC
Place of Publication:	CARY
ISSN:	1523-5866
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MGMT PROMOTER METHYLATION; CLASSIFICATION; OLIGODENDROGLIOMA; ASTROCYTOMAS; PROCARBAZINE; SURVIVAL; DIFFUSE; TUMORS; ATRX; AGE Multiple languages Oncology; Clinical Neurology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/25794